Albumin Bilirubin Index as a Predictor of Outcome of Variceal Bleeding
Launched by ASSIUT UNIVERSITY · Sep 24, 2024
Trial Information
Current as of December 21, 2024
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a tool called the Albumin Bilirubin Index to see if it can help predict how patients will do after experiencing variceal bleeding, which is bleeding from swollen blood vessels in the liver. The researchers hope that by understanding this better, they can improve treatment and outcomes for patients who face this serious condition.
To join the study, participants need to be between 18 and 80 years old and should not have certain health issues like liver cancer or blood diseases. Those who take part can expect regular check-ups and assessments to monitor their health and how well the Albumin Bilirubin Index works in predicting outcomes after variceal bleeding. This trial is currently looking for volunteers, and it’s open to all genders.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age between 18-80 years old
- Exclusion Criteria:
- • Hcc Hematological disease
Trial Officials
Heba Sayed Zaki
Principal Investigator
Assiut University
About Assiut University
Assiut University, a prominent academic institution located in Egypt, is dedicated to advancing medical research and clinical trials that enhance healthcare outcomes. With a strong emphasis on innovation and collaboration, the university engages in a wide array of clinical studies across various disciplines, aiming to contribute valuable insights into disease prevention, diagnosis, and treatment. Assiut University's commitment to ethical research practices and rigorous scientific methodology ensures the integrity and reliability of its clinical trials, ultimately benefiting both the local community and the global medical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Assiut, , Egypt
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0